Abstract: Substituted tetrahydrofuran analogs of F-series prostaglandins and methods of their use in treating glaucoma and ocular hypertension are disclosed.
Type:
Grant
Filed:
July 2, 1998
Date of Patent:
February 15, 2000
Assignee:
Alcon Laboratories, Inc.
Inventors:
Robert D. Selliah, Mark R. Hellberg, Peter G. Klimko, Verney L. Sallee, Paul W. Zinke
Abstract: Disclosed is the use of platelet derived growth factor for the enhancement of wound healing wherein the growth factor is either singularly or multiply dosed on a single day, rather than multiply dosed over a number of days. Also disclosed are pharmaceutical compositions comprising platelet derived growth factor.
Abstract: Disclosed is the use of cloprostenol and fluprostenol analogues for the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic compositions comprising said compounds.
Type:
Grant
Filed:
August 21, 1997
Date of Patent:
March 30, 1999
Assignee:
Alcon Laboraties, Inc.
Inventors:
Peter G. Klimko, John E. Bishop, Verney L. Sallee, Paul W. Zinke
Abstract: Keto-substituted tetrahydrofuran analogs of prostaglandins and methods of their use in treating glaucoma and ocular hypertension are disclosed.
Abstract: Combinations of at least one clonidine derivative and at least one prostaglandin are used to treat glaucoma and ocular hypertension without some of the side effects typically associated with topical administration of prostaglandins.
Abstract: Certain prostaglandin analogues are useful in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandin analogues.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
September 15, 1998
Assignee:
Alcon Laboratories, Inc.
Inventors:
Peter G. Klimko, Robert D. Selliah, Thomas R. Dean, Mark R. Hellberg, John E. Bishop
Abstract: 9-Halo-13,14-dihydroprostaglandins are useful in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandins.
Type:
Grant
Filed:
December 15, 1993
Date of Patent:
February 24, 1998
Assignee:
Alcon Laboratories, Inc.
Inventors:
Verney L. Sallee, Louis DeSantis, Jr., Paul W. Zinke, John E. Bishop
Abstract: Disclosed are 9-deoxyprostaglandins which are useful in the treatment of glaucoma and ocular hypertension. Some of these 9-deoxyprostaglandins are novel. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandins.
Type:
Grant
Filed:
June 7, 1995
Date of Patent:
December 16, 1997
Assignee:
Alcon Laboratories, Inc.
Inventors:
Mark R. Hellberg, Thomas R. Dean, Paul W. Zinke, Robert D. Selliah, John E. Bishop
Abstract: Disclosed is the use of cloprostenol and fluprostenol analogues for the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic compositions comprising said compounds.
Type:
Grant
Filed:
December 18, 1996
Date of Patent:
September 9, 1997
Assignee:
Alcon Laboratories, Inc.
Inventors:
Peter G. Klimko, John E. Bishop, Verney L. Sallee, Paul W. Zinke
Abstract: Compositions and methods are provided for cleaning and wetting of contact lenses, especially rigid, gas-permeable contact lenses. The compositions comprise low molecular weight polyalkylene oxide modified siloxanes, which are particularly effective in removing lipids from the surface of contact lenses.
Type:
Grant
Filed:
March 14, 1995
Date of Patent:
August 5, 1997
Assignee:
Alcon Laboratories, Inc.
Inventors:
Nayan N. Desai, Ronald P. Quintana, Masood A. Chowhan
Abstract: 9-Haloprostaglandins are useful in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising such prostaglandins.
Abstract: Combinations of at least one clonidine derivative and at least one prostaglandin are used to treat glaucoma and ocular hypertension without some of the side effects typically associated with topical administration of prostaglandins.
Abstract: Disclosed is the use of combinations of F and E series prostaglandins and their respective derivatives and analogues, as well as pharmaceutically acceptable salts and esters thereof in the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic, pharmaceutical compositions comprising said combinations.
Abstract: Disclosed are novel compositions comprising mixtures useful to treat the metabolically impaired and to improve patient compliance. Included are non-racemic mixtures of certain chiral spirofluorenehydantoins. Methods of use to treat glucose toxicity and complications arising from diabetes mellitus are also disclosed.
Abstract: Disclosed is the use of cloprostenol, fluprostenol, and their pharmaceutically acceptable salts and esters for the treatment of glaucoma and ocular hypertension. Also disclosed are ophthalmic compositions comprising said compounds.
Type:
Grant
Filed:
August 3, 1993
Date of Patent:
April 23, 1996
Assignee:
Alcon Laboratories, Inc.
Inventors:
John E. Bishop, Louis DeSantis, Jr., Verney L. Sallee
Abstract: Combinations of at least one clonidine derivative and at least one prostaglandin are used to treat glaucoma and ocular hypertension without some of the side effects typically associated with topical administration of prostaglandins.